Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

References

• EmsleyRChilizaBAsmalLHarveyBHThe nature of relapse in schizophreniaBMC Psychiatry2013135023394123
   PubMed Web of Science ®Google Scholar
• KarsonCDuffyRAEramoANylanderAGOffordSJLong-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic reviewNeuropsychiatr Dis Treat201612576726792993
   PubMed Web of Science ®Google Scholar
• De HertMSermonJGeertsPVansteelandtKPeuskensJDetrauxJThe use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychoticsCNS Drugs201529863765826293744
   PubMed Web of Science ®Google Scholar
• MorkenGWidenJHGraweRWNon-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry200883218447935
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHFariesDEZhuBErnstFRSwartzMSSwansonJWMedication adherence and long-term functional outcomes in the treatment of schizophrenia in usual careJ Clin Psychiatry200667345346016649833
   PubMed Web of Science ®Google Scholar
• SendtKVTracyDKBhattacharyyaSA systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disordersPsychiatry Res20152251–2143025466227
   PubMed Web of Science ®Google Scholar
• SchennachRObermeierMMeyerSPredictors of relapse in the year after hospital discharge among patients with schizophreniaPsychiatr Serv2012631879022227766
   PubMed Web of Science ®Google Scholar
• WangXZhangWMaNAdherence to antipsychotic medication by community-based patients with schizophrenia in China: a cross-sectional studyPsychiatr Serv201667443143726725294
   PubMed Web of Science ®Google Scholar
• XiaoJMiWLiLShiYZhangHHigh relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s Republic of ChinaNeuropsychiatr Dis Treat2015111161116726056450
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCASliwaJKFuDJMaYWHulihanJPaliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychoticsNeuropsychiatr Dis Treat2013934135023493643
   PubMed Web of Science ®Google Scholar
• AgidOFoussiasGRemingtonGLong-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse preventionExpert Opin Pharmacother201011142301231720586707
   PubMed Web of Science ®Google Scholar
• TiihonenJHaukkaJTaylorMHaddadPMPatelMXKorhonenPA nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophreniaAm J Psychiatry2011168660360921362741
   PubMed Web of Science ®Google Scholar
• LeuchtCHeresSKaneJMKisslingWDavisJMLeuchtSOral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trialsSchizophr Res20111271–3839221257294
   PubMed Web of Science ®Google Scholar
• SchreinerAAadamsooKAltamuraCA randomized, active-controlled rater-blinded 2-year study of paliperidone palmitate versus investigators’ choice of oral antipsychotic monotherapy in patients with schizophrenia (prosipal)Eur Psychiatry201429Suppl 1124119631
   PubMed Web of Science ®Google Scholar
• CitromeLPaliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medicationInt J Clin Pract201064221623919886879
   PubMed Web of Science ®Google Scholar
• NewtonRHustigHLakshmanaRPractical guidelines on the use of paliperidone palmitate in schizophreniaCurr Med Res Opin201228455956722321007
   PubMed Web of Science ®Google Scholar
• LiHTurkozIZhangFEfficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative studyNeuropsychiatr Dis Treat201512152426730193
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCASliwaJKMaYWTurnerNOnset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trialAnn Gen Psychiatry20111011221481243
   PubMed Web of Science ®Google Scholar
• BossieCAFuDJSliwaJKMaYWAlphsLTolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trialTher Adv Psychopharmacol20111411112423983935
   PubMedGoogle Scholar
• FuDJBossieCASliwaJKMaYWAlphsLPaliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparisonInt Clin Psychopharmacol2014291455524113628
   PubMed Web of Science ®Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol201013563564719941696
   PubMed Web of Science ®Google Scholar
• PandinaGLaneRGopalSA double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophreniaProg Neuropsychopharmacol Biol Psychiatry201135121822621092748
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol201030323524420473057
   PubMed Web of Science ®Google Scholar
• GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol201025524725620389255
   PubMed Web of Science ®Google Scholar
• LiHRuiQNingXXuHGuNA comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20113541002100821315787
   PubMed Web of Science ®Google Scholar
• SiTZhangKTangJEfficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional studyNeuropsychiatr Dis Treat2015111483149226150719
   PubMed Web of Science ®Google Scholar
• TakahashiNTakahashiMSaitoTRandomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophreniaNeuropsychiatr Dis Treat2013818891898
   PubMed Web of Science ®Google Scholar
• SliwaJKBossieCAFuDJTurkozIAlphsLLong-term toler-ability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophreniaNeuropsychiatr Dis Treat2012837538522956873
   PubMed Web of Science ®Google Scholar
• AttardAOlofinjanaOCorneliusVCurtisVTaylorDPaliperidone palmitate long-acting injection – prospective year-long follow-up of use in clinical practiceActa Psychiatr Scand20141301465124117209
   PubMed Web of Science ®Google Scholar
• CoppolaDLiuYGopalSA one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophreniaBMC Psychiatry2012122622455454
   PubMed Web of Science ®Google Scholar
• GopalSVijapurkarULimPMorozovaMEerdekensMHoughDA 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophreniaJ Psychopharmacol201125568569720615933
   PubMed Web of Science ®Google Scholar
• HoughDGopalSVijapurkarULimPMorozovaMEerdekensMPaliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled studySchizophr Res20101162–310711719959339
   PubMed Web of Science ®Google Scholar
• ZhangFSiTChiouCFEfficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophreniaNeuropsychiatr Dis Treat20151165766825792835
   PubMed Web of Science ®Google Scholar
• SavitzAJXuHGopalSEfficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority studyInt J Neuropsychopharmacol2016197
   PubMed Web of Science ®Google Scholar
• MarderSRDavisJMChouinardGThe effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trialsJ Clin Psychiatry199758125385469448657
   PubMed Web of Science ®Google Scholar
• BusnerJTargumSDThe clinical global impressions scale: applying a research tool in clinical practicePsychiatry (Edgmont)2007472837
   PubMedGoogle Scholar
• MorosiniPLMaglianoLBrambillaLUgoliniSPioliRDevelopment, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioningActa Psychiatr Scand2000101432332910782554
   PubMed Web of Science ®Google Scholar
• GharabawiGMGreenspanARupnowMFReduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trialBMC Psychiatry200664517054789
   PubMed Web of Science ®Google Scholar
• VernonMKRevickiDAAwadAGPsychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patientsSchizophr Res20101181–327127820172695
   PubMed Web of Science ®Google Scholar
• ThompsonKKulkarniJSergejewAAReliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychosesSchizophr Res200042324124710785582
   PubMed Web of Science ®Google Scholar
• FialkoLGaretyPAKuipersEA large-scale validation study of the Medication Adherence Rating Scale (MARS)Schizophr Res20081001–3535918083007
   PubMed Web of Science ®Google Scholar
• van WijngaardenBScheneAKoeterMPeople with schizophrenia in five countries: conceptual similarities and intercultural differences in family caregivingSchizophr Bull200329357358614609250
   PubMed Web of Science ®Google Scholar
• GuyWEarly Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for PsychopharmacologyRockville, MDNational Institute of Mental Health1976
   Google Scholar
• BarnesTRA rating scale for drug-induced akathisiaBr J Psychiatry19891546726762574607
   PubMed Web of Science ®Google Scholar
• SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
   PubMedGoogle Scholar
• LiebermanJJodyDGeislerSTime course and biologic correlates of treatment response in first-episode schizophreniaArch Gen Psychiatry19935053693768098203
   PubMed Web of Science ®Google Scholar
• McGlashanTHJohannessenJOEarly detection and intervention with schizophrenia: rationaleSchizophr Bull19962222012228782282
   PubMed Web of Science ®Google Scholar
• AlphsLBossieCMaoLLeeEStarrHLTreatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvementEarly Interv Psychiatry Epub2015925
   Google Scholar
• SubotnikKLCasausLRVenturaJLong-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trialJAMA Psychiatry201572882282926107752
   PubMed Web of Science ®Google Scholar
• HoughDLindenmayerJPGopalSSafety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophreniaProg Neuropsychopharmacol Biol Psychiatry20093361022103119481579
   PubMed Web of Science ®Google Scholar
• HargarterLCherubinPBergmansPIntramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychoticsProg Neuropsychopharmacol Biol Psychiatry2015581725448776
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) InvestigatorsEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• MarcusSCZummoJPettitARStoddardJDoshiJAAntipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital dischargeJ Manag Care Spec Pharm201521975476826308223
   PubMed Web of Science ®Google Scholar
• GeertsPMartinezGSchreinerAAttitudes towards the administration of long-acting antipsychotics: a survey of physicians and nursesBMC Psychiatry2013135823414331
   PubMed Web of Science ®Google Scholar
• WaddellLTaylorMAttitudes of patients and mental health staff to antipsychotic long-acting injections: systematic reviewBr J Psychiatry Suppl200952S43S5019880916
   PubMedGoogle Scholar
• HeresSReichhartTHamannJMendelRLeuchtSKisslingWPsychiatrists’ attitude to antipsychotic depot treatment in patients with first-episode schizophreniaEur Psychiatry201126529730120570493
   PubMed Web of Science ®Google Scholar
• PatelMXHaddadPMChaudhryIBMcLoughlinSHusainNDavidASPsychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 yearsJ Psychopharmacol201024101473148219477883
   PubMed Web of Science ®Google Scholar
• KwonJSKimSNHanJSatisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychoticsInt Clin Psychopharmacol201530632032826196188
   PubMed Web of Science ®Google Scholar
• KaplanGCasoyJZummoJImpact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaPatient Prefer Adherence201371171118024265549
   PubMed Web of Science ®Google Scholar
• StevensGLDawsonGZummoJClinical benefits and impact of early use of long-acting injectable antipsychotics for schizophreniaEarly Interv Psychiatry201610536537726403538
   PubMed Web of Science ®Google Scholar
• González-RodríguezACatálanRPenadésRProfile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a reviewPatient Prefer Adherence2015969570626082620
   PubMedGoogle Scholar
• Caqueo-UrízarARus-CalafellMUrzúaAEscuderoJGutiérrez-MaldonadoJThe role of family therapy in the management of schizophrenia: challenges and solutionsNeuropsychiatr Dis Treat20151114515125609970
   PubMed Web of Science ®Google Scholar
• ShulerKMApproaches to improve adherence to pharmacotherapy in patients with schizophreniaPatient Prefer Adherence2014870171424868149
   PubMed Web of Science ®Google Scholar
• PalmerBAPankratzVSBostwickJMThe lifetime risk of suicide in schizophrenia: a reexaminationArch Gen Psychiatry200562324725315753237
   PubMed Web of Science ®Google Scholar
• HorKTaylorMSuicide and schizophrenia: a systematic review of rates and risk factorsJ Psychopharmacol2010244 Suppl819020923923
   PubMed Web of Science ®Google Scholar
• NockMKBorgesGBrometEJCross-national prevalence and risk factors for suicidal ideation, plans and attemptsBr J Psychiatry200819229810518245022
   PubMed Web of Science ®Google Scholar
• KesslerRCBorgesGWaltersEEPrevalence of and risk factors for lifetime suicide attempts in the National Comorbidity SurveyArch Gen Psychiatry199956761762610401507
   PubMed Web of Science ®Google Scholar
• VijayakumarLSuicide and mental disorders in AsiaInt Rev Psychiatry200517210911416194780
   PubMed Web of Science ®Google Scholar
• PhillipsMRYangGLiSLiYSuicide and the unique prevalence pattern of schizophrenia in mainland China: a retrospective observational studyLancet2004364943910621068
   Web of Science ®Google Scholar
• XiangYTWengYZLeungCMTangWKUngvariGSSociodemographic and clinical correlates of lifetime suicide attempts and their impact on quality of life in Chinese schizophrenia patientsJ Psychiatr Res200842649550217663994
   PubMed Web of Science ®Google Scholar
• LyuJZhangJCharacteristics of schizophrenia suicides compared with suicides by other diagnosed psychiatric disorders and those without a psychiatric disorderSchizophr Res20141551–3596524657011
   PubMed Web of Science ®Google Scholar
• PhillipsMRYangGZhangYWangLJiHZhouMRisk factors for suicide in China: a national case-control psychological autopsy studyLancet200236093471728173612480425
   PubMed Web of Science ®Google Scholar
• LuiSYRisk factors for deliberate self-harm and completed suicide in young Chinese people with schizophreniaAust N Z J Psychiatry200943325225919221914
   PubMed Web of Science ®Google Scholar
• SirisSGSuicide and schizophreniaJ Psychopharmacol200115212713511448086
   PubMed Web of Science ®Google Scholar
• ZhangXYAl JurdiRKZoghbiAWPrevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophreniaJ Psychiatr Res201347101370137523791457
   PubMed Web of Science ®Google Scholar
• MontrossLPKasckowJGolshanSSolorzanoELehmanDZisookSSuicidal ideation and suicide attempts among middle-aged and older patients with schizophrenia spectrum disorders and concurrent subsyn-dromal depressionJ Nerv Ment Dis20081961288489019077855
   PubMed Web of Science ®Google Scholar
• SuominenKIsometsäESuokasJHaukkaJAchteKLönnqvistJCompleted suicide after a suicide attempt: a 37-year follow-up studyAm J Psychiatry2004161356256314992984
   PubMed Web of Science ®Google Scholar
• MeltzerHYAlphsLGreenAIInternational Suicide Prevention Trial Study GroupClozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT)Arch Gen Psychiatry2003601829112511175
   PubMed Web of Science ®Google Scholar
• SahaSChantDMcGrathJA systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?Arch Gen Psychiatry200764101123113117909124
   PubMed Web of Science ®Google Scholar
• IfteniPCorrellCUBurteaVKaneJMManuPSudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatientsSchizophr Res20141551–3727624704220
   PubMed Web of Science ®Google Scholar
• LiuTSongXChenGParadisADZhengXPrevalence of schizophrenia disability and associated mortality among Chinese men and womenPsychiatry Res20142201–218118725113924
   PubMed Web of Science ®Google Scholar
• RanMSMaoWJChanCLChenEYConwellYGender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up studyBr J Psychiatry2015206428328825573398
   PubMed Web of Science ®Google Scholar
• PiercePGopalSSavitzAPaliperidone palmitate: Japanese postmarketing mortality results in patients with schizophreniaCurr Med Res Opin201619
   Web of Science ®Google Scholar
• StromBLEngSMFaichGComparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)Am J Psychiatry2011168219320121041245
   PubMed Web of Science ®Google Scholar